secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0000879407-26-000045
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license
--------------------------------------------------------------------------------

- Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).
- REDEMPLO launch: >400 prescriptions, ~180 patients shipped, ~30 new scripts/week, 85% APOC3-naive patients.
- Licensed ARO-PNPLA3 to Madrigal for $25M upfront, up to $975M milestones, tiered royalties (high-single to mid-teens).
- Raised $930M: $700M zero-coupon converts due 2032 (35% premium) and $230M stock at $64.50/sh.
- Obesity: ARO-INHBE combo -9.4% weight loss wk16 (vs -4.8%); ARO-ALK7 -88% mRNA knockdown, -14.1% visceral fat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/0000879407-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/arwr-20260507.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer